173 related articles for article (PubMed ID: 35035044)
21. Novel method for quantitative ANA measurement using near-infrared imaging.
Peterson LK; Wells D; Shaw L; Velez MG; Harbeck R; Dragone LL
J Immunol Methods; 2009 Sep; 349(1-2):1-8. PubMed ID: 19720064
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of antinuclear antibodies by indirect immunofluorescence and line immunoassay methods': four years' data from Turkey.
Sener AG; Afsar I; Demirci M
APMIS; 2014 Dec; 122(12):1167-70. PubMed ID: 24735346
[TBL] [Abstract][Full Text] [Related]
23. Hep-2000 indirect immunofluorescence assay - an emerging screening tool for detection of antinuclear autoantibodies in various connective tissue disorders.
Singh A; Sahu S; Jadhav NR; Kaur N
Indian J Pathol Microbiol; 2024 Jun; ():. PubMed ID: 38847177
[TBL] [Abstract][Full Text] [Related]
24. An indirect comparison of automated indirect immunofluorescence vs automated solid-phase immunoassays for antinuclear antibody detection: A meta-analysis and adjusted indirect comparison of diagnostic test accuracy.
Zhang M; Zhang X
Int J Rheum Dis; 2022 Sep; 25(9):991-1002. PubMed ID: 35726725
[TBL] [Abstract][Full Text] [Related]
25. Clinical value of anti-DFS70 antibodies in a cohort of patients undergoing routine antinuclear antibodies testing.
Yumuk Z; Demir M
J Immunol Methods; 2020 May; 480():112754. PubMed ID: 32057435
[TBL] [Abstract][Full Text] [Related]
26. Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases.
Alsaed OS; Alamlih LI; Al-Radideh O; Chandra P; Alemadi S; Al-Allaf AW
Sci Rep; 2021 Apr; 11(1):8229. PubMed ID: 33859213
[TBL] [Abstract][Full Text] [Related]
27. Measurement of antinuclear antibodies and their fine specificities: time for a change in strategy?
Otten HG; Brummelhuis WJ; Fritsch-Stork R; Leavis HL; Wisse BW; van Laar JM; Derksen RHWM
Clin Exp Rheumatol; 2017; 35(3):462-470. PubMed ID: 28240588
[TBL] [Abstract][Full Text] [Related]
28. Laboratory screening of connective tissue diseases by a new automated ENA screening assay (EliA Symphony) in clinically defined patients.
González C; García-Berrocal B; Pérez M; Navajo JA; Herraez O; González-Buitrago JM
Clin Chim Acta; 2005 Sep; 359(1-2):109-14. PubMed ID: 15894301
[TBL] [Abstract][Full Text] [Related]
29. A hierarchical bivariate meta-analysis of diagnostic test accuracy to provide direct comparisons of immunoassays vs. indirect immunofluorescence for initial screening of connective tissue diseases.
Orme ME; Andalucia C; Sjölander S; Bossuyt X
Clin Chem Lab Med; 2021 Feb; 59(3):547-561. PubMed ID: 32352399
[TBL] [Abstract][Full Text] [Related]
30. Analysis of DFS70 pattern and impact on ANA screening using a novel HEp-2 ELITE/DFS70 knockout substrate.
Malyavantham K; Suresh L
Auto Immun Highlights; 2017 Dec; 8(1):3. PubMed ID: 28315185
[TBL] [Abstract][Full Text] [Related]
31. Identification of specific antinuclear antibodies in dogs using a line immunoassay and enzyme-linked immunosorbent assay.
Bremer HD; Lattwein E; Renneker S; Lilliehöök I; Rönnelid J; Hansson-Hamlin H
Vet Immunol Immunopathol; 2015 Dec; 168(3-4):233-41. PubMed ID: 26547884
[TBL] [Abstract][Full Text] [Related]
32. [Modern look at the problems of investigation of antinuclear antibodies in systemic lupus erythematosus (literature review).].
Aleksandrova EN; Verizhnikova ZG; Novikov AA; Lukina GV
Klin Lab Diagn; 2018; 63(6):340-348. PubMed ID: 30702224
[TBL] [Abstract][Full Text] [Related]
33. Performance of antinuclear antibody connective tissue disease screen.
López-Hoyos M; Rodríguez-Valverde V; Martinez-Taboada V
Ann N Y Acad Sci; 2007 Aug; 1109():322-9. PubMed ID: 17785321
[TBL] [Abstract][Full Text] [Related]
34. Solid phase assays versus automated indirect immunofluorescence for detection of antinuclear antibodies.
Claessens J; Belmondo T; De Langhe E; Westhovens R; Poesen K; Hüe S; Blockmans D; Mahler M; Fritzler MJ; Bossuyt X
Autoimmun Rev; 2018 Jun; 17(6):533-540. PubMed ID: 29526634
[TBL] [Abstract][Full Text] [Related]
35. A Negative Antinuclear Antibody Does Not Indicate Autoantibody Negativity in Myositis: Role of Anticytoplasmic Antibody as a Screening Test for Antisynthetase Syndrome.
Aggarwal R; Dhillon N; Fertig N; Koontz D; Qi Z; Oddis CV
J Rheumatol; 2017 Feb; 44(2):223-229. PubMed ID: 27909085
[TBL] [Abstract][Full Text] [Related]
36. Clinical use of anti-DFS70 autoantibodies.
Kang SY; Lee WI; Kim MH; La Jeon Y
Rheumatol Int; 2019 Aug; 39(8):1423-1429. PubMed ID: 30972541
[TBL] [Abstract][Full Text] [Related]
37. Cost-effective detection of non-antidouble-stranded DNA antinuclear antibody specificities in daily clinical practice.
Vos PA; Bast EJ; Derksen RH
Rheumatology (Oxford); 2006 May; 45(5):629-35. PubMed ID: 16368728
[TBL] [Abstract][Full Text] [Related]
38. Analysis of antinuclear antibody titers and patterns by using HEp-2 and primate liver tissue substrate indirect immunofluorescence assay in patients with systemic autoimmune rheumatic diseases.
Wei Q; Jiang Y; Xie J; Lv Q; Xie Y; Tu L; Xiao M; Wu Z; Gu J
J Clin Lab Anal; 2020 Dec; 34(12):e23546. PubMed ID: 33047841
[TBL] [Abstract][Full Text] [Related]
39. Range of antinuclear antibodies in "healthy" individuals.
Tan EM; Feltkamp TE; Smolen JS; Butcher B; Dawkins R; Fritzler MJ; Gordon T; Hardin JA; Kalden JR; Lahita RG; Maini RN; McDougal JS; Rothfield NF; Smeenk RJ; Takasaki Y; Wiik A; Wilson MR; Koziol JA
Arthritis Rheum; 1997 Sep; 40(9):1601-11. PubMed ID: 9324014
[TBL] [Abstract][Full Text] [Related]
40. [Investigation of antinuclear antibodies in chronic hepatitis B patients].
Şener AG; Aydın N; Ceylan C; Kırdar S
Mikrobiyol Bul; 2018 Oct; 52(4):425-430. PubMed ID: 30522427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
